Abstract: Recombinant enzymes BesA, BesB, BesC, BesD and/or BesE are used generate non-canonical amino acids comprising a useful functional group, such as an alkynlyl, alkenyl or halogen.
Type:
Grant
Filed:
October 13, 2019
Date of Patent:
August 24, 2021
Assignee:
The Regents of the University of California
Inventors:
Michelle C. Y. Chang, Jorge A. Marchand Benmaman, Monica E. Neugebauer
Abstract: The present invention relates to a method for the recombinant production of a serine protease comprising (a) culturing a host cell comprising one or more vectors, wherein the one or more vectors encode in expressible form the serine protease and a proteinaceous inhibitor of the serine protease, wherein the proteinaceous inhibitor of the serine protease is heterologous with respect to the serine protease, under conditions wherein the serine protease and the proteinaceous inhibitor of the serine protease are expressed; or (a?) culturing a host cell the genome of which encodes in expressible form the serine protease and a proteinaceous inhibitor of the serine protease, wherein the proteinaceous inhibitor of the serine protease is heterologous with respect to the serine protease, and wherein the coding sequences of the serine protease and/or the proteinaceous inhibitor have been introduced into the host cell genome by applying a CRISPR technology, under conditions wherein the serine protease and the proteinaceous
Abstract: The present disclosure provides compositions, methods, kits, systems and apparatus that are useful for nucleic acid polymerization. In particular, modified polymerases and biologically active fragments thereof are provided that allow for nucleic acid amplification. In some aspects, the disclosure provides modified polymerases having lower systematic error as compared to a reference polymerase. In one aspect, the disclosure relates to modified polymerases useful for nucleic acid sequencing, genotyping, copy number variation analysis, paired-end sequencing and other forms of genetic analysis. In some aspects, the disclosure relates to modified polymerases useful for the generation of nucleic acid libraries or nucleic acid templates. In some aspects, the disclosure relates to the identification of homologous amino acid mutations that can be transferred across classes or families of polymerases to provide novel polymerases with altered properties.
Type:
Grant
Filed:
June 5, 2020
Date of Patent:
August 17, 2021
Assignee:
Life Technologies Corporation
Inventors:
Peter Vander Horn, Daniel Mazur, Theo Nikiforov, Mindy Landes, Eileen Tozer
Abstract: The present invention relates to a fusion protein selectively binding collagen and having ectonucleotidase activity. The fusion protein comprises an amino acid sequence of the extracellular domain of glycoprotein VI fused via a first linker sequence to the N-terminus of an amino acid sequence of an Fc region, whereby the C-terminus of the Fc region is linked via a second linker sequence to an amino acid sequence of the extracellular domain of a CD39 protein. The fusion protein is useful in the treatment or prevention of cardiovascular disease or diabetes, such as in the treatment of acute atherothrombotic events with a favorable risk-benefit ratio.
Type:
Grant
Filed:
July 3, 2018
Date of Patent:
July 27, 2021
Assignee:
ADVANCECOR GMBH
Inventors:
Heidrun Degen, Silvia Goebel, Kristin Adler, Martin Ungerer
Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
Type:
Grant
Filed:
October 18, 2019
Date of Patent:
July 20, 2021
Assignee:
ModernaTX, Inc.
Inventors:
Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
Abstract: The present invention provides a method for producing glycine or a salt thereof by fermentation of a bacterium which has been modified to overexpress a gene encoding a protein having L-threonine 3-dehydrogenase activity and a gene encoding a protein having 2-amino-3-oxobutanoate coenzyme A ligase activity. The bacterium can be, for example, a coryneform bacterium or a bacterium belonging to the family Enterobacteriaceae.
Abstract: A chromatographic method for collecting blood coagulation factor VII (Factor VII) and/or activated blood coagulation factor VII (activated Factor VII) from plasma-derived fractions with high yield is provided. In accordance with the method of the present invention, Factor VII and/or activated Factor VII of interest can be collected with a recovery rate of as high as 90% or more by letting Factor VII and/or activated Factor VII which fails to be adsorbed to a first anion exchange resin and remains in a non-adsorption fraction be adsorbed in a second anion exchange resin.
Abstract: Provided are compositions and methods for enhancing recombinant protein production. The compositions and methods involve use of Ribose Binding Protein (RBP) as a segment of a fusion polypeptide, whereby the RBP segment enhances production of the fusion protein. The fusion proteins contain the RBP sequentially in a single fusion protein with a polypeptide for which enhanced expression is desired. Recombinant expression vectors encoding the fusion proteins that contain and RBP segment are included, as are cells that contain the expression vectors. Methods for separating fusion proteins and for liberating a polypeptide segment that is part of the fusion protein are also provided.
Type:
Grant
Filed:
February 11, 2019
Date of Patent:
July 6, 2021
Assignee:
The Research Foundation for the State University of New York
Inventors:
Stewart N. Loh, Jeung-Hoi Ha, Adam R. Blanden, Alan Blayney
Abstract: The present disclosure provides activated formylglycine-generating enzymes (FGE), methods of producing activated FGE, and their use in methods of producing a protein comprising a formylglycine (FGly) residue. The methods of producing activated FGE, as well as methods of use of activated FGE in producing FGly-containing proteins, include both cell-based and cell-free methods. Compositions and kits that find use, e.g., in practicing the methods of the present disclosure are also provided.
Type:
Grant
Filed:
May 4, 2020
Date of Patent:
July 6, 2021
Assignee:
R.P. Scherer Technologies, LLC
Inventors:
David Rabuka, Gregory W. deHart, Patrick Holder, Jeanne Baker
Abstract: Methods for increasing carbon-based chemical product yield in an organism by increasing carbon uptake and/or altering a pathway to or from an overflow metabolite in the organism, nonnaturally occurring organisms having increased carbon-based chemical product yield with increased carbon uptake and/or an altered pathway to or from an overflow metabolite, and methods for producing a carbon-based chemical product with these organisms are provided.
Type:
Grant
Filed:
April 30, 2019
Date of Patent:
July 6, 2021
Assignee:
INV Nylon Chemicals Americas, LLC
Inventors:
Alexander Brett Foster, Ana Teresa dos Santos Brito Mendes Roberts, Arghya Barman, Jonathan Kennedy
Abstract: The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.
Abstract: The present invention provides a lactoferrin fusion protein having high clinical utility and a production method therefor. The present invention further provides: a lactoferrin fusion protein that retains the biological activity of native lactoferrin while having a significantly extended in vivo life span, and that has more clinical utility than native lactoferrin and recombinant lactoferrin; and a production method therefor. With this fusion protein or a variant thereof, the ability of lactoferrin to bind iron is retained, and therefore at least the important biological activity of lactoferrin that is based on the iron-binding ability is retained. Additionally, this fusion protein or variant thereof has bioavailability and resistance to protease, and thus can exhibit biological activity in vivo over a long period. Furthermore, this fusion protein is not easily broken down by pepsin in the stomach.
Abstract: There is provided chimeric polypeptides capable of converting xylose to xylulose, engineered host cells that express the chimeric polypeptides, methods of creating chimeric polypeptides, and methods of fermenting cellulosic biomass to produce biofuels, including ethanol.
Abstract: A process for the production of lipids from biomass derived from guayule plants comprising: obtaining a hydrolysate comprising 5 carbon atom (C5) sugars from biomass derived from guayule plants, said 5 carbon atom (C5) sugars being present in said hydrolysate in a quantity greater than or equal to 80% by weight, preferably ranging from 85% by weight to 99% by weight, with respect to the total weight of said hydrolysate; feeding said hydrolysate to a fermentation device in the presence of at least one oleaginous yeast to obtain a fermentation broth; at the end of fermentation, subjecting said fermentation broth to separation obtaining an aqueous suspension of oleaginous cellular biomass comprising lipids and an aqueous phase. The lipids thus obtained can be advantageously used in the production of biofuel such as, for example, biodiesel or green diesel that can be used as such, or in mixtures with other fuels, for automotive transport.
Abstract: Recombinant microorganisms configured for enhanced production of compounds such as 2-pyrone-4,6-dicarboxylic acid (PDC) and methods of using the recombinant microorganisms for the production of these compounds. The recombinant microorganisms include one or more modifications that reduce 2-pyrone-4,6-dicarboxylic acid (PDC) hydrolase activity, 4-carboxy-2-hydroxy-6-methoxy-6-oxohexa-2,4-dienoate (CHMOD) cis-trans isomerase activity, 4-carboxy-2-hydroxy-6-methoxy-6-oxohexa-2,4-dienoate (CHMOD) methyl esterase activity, and/or vanillate/3-O-methylgallate O-demethylase activity. The recombinant microorganisms can be used to generate PDC from media comprising plant-derived phenolics, such as syringyl phenolics, guaiacyl phenolics, and p-hydroxyphenyl phenolics. The plant-derived phenolics can be derived from pretreated lignin, including depolymerized lignin or other chemically altered lignin.
Type:
Grant
Filed:
February 19, 2020
Date of Patent:
June 8, 2021
Assignee:
WISCONSIN ALUMNI RESEARCH FOUNDATION
Inventors:
Daniel R. Noguera, Timothy James Donohue, Jose Perez, Wayne S. Kontur, German Eduardo Umana Chapeton
Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.
Type:
Grant
Filed:
July 20, 2016
Date of Patent:
May 18, 2021
Assignee:
SEATTLE CHILDREN'S RESEARCH INSTITUTE
Inventors:
Andrew M. Scharenberg, Michael T. Certo, Kamila Sabina Gwiazda
Abstract: Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity.
Type:
Grant
Filed:
May 11, 2020
Date of Patent:
May 11, 2021
Assignee:
The Regents of the University of California
Inventors:
Daniel Garrido, J. Bruce German, Garlito B. Lebrilla, David A. Mills
Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.
Type:
Grant
Filed:
November 23, 2015
Date of Patent:
May 4, 2021
Assignee:
SEATTLE CHILDREN'S RESEARCH INSTITUTE
Inventors:
Andrew M. Scharenberg, Michael T. Certo, Kamila Sabina Gwiazda
Abstract: Reaction solutions are disclosed herein comprising water, sucrose and a glucosyltransferase enzyme that synthesizes poly alpha-1,3-glucan. The glucosyltransferase enzyme can synthesize insoluble glucan polymer having at least 50% alpha-1,3 glycosidic linkages and a number average degree of polymerization of at least 100. Further disclosed are methods of using such glucosyltransferase enzymes to produce insoluble poly alpha-1,3-glucan.
Type:
Grant
Filed:
February 14, 2020
Date of Patent:
April 27, 2021
Assignee:
NUTRITION & BIOSCIENCES USA 4, INC.
Inventors:
Mark S. Payne, Yefim Brun, Hongxian He, Thomas Scholz